Publications by authors named "Olympia Apostolopoulou"
Article Synopsis
- Recent studies indicate that severe COVID-19 can cause coagulation issues linked to inflammation, hypoxia, and endothelial dysfunction, suggesting anticoagulation therapy may be crucial for patient management.
- A 73-year-old patient diagnosed with COVID-19 experienced severe symptoms leading to respiratory failure and required intensive care, during which he was treated with various medications and received prophylactic anticoagulation.
- Following the identification of a right atrium thrombus and subsequent adjustment to therapeutic anticoagulation, the patient showed significant clinical improvement, underscoring the importance of imaging and tailored treatment in COVID-19 cases.
Objectives: To study the population pharmacokinetics of micafungin in critically ill patients, evaluate and optimize dosage regimens.
Methods: An HPLC-fluorescence bioassay for micafungin was developed, fully validated and applied to a pharmacokinetic study conducted in 14 ICU patients. Dense blood sampling was performed from days 1 to 7.
Comparative pharmacokinetics of the three echinocandins in ICU patients.
J Antimicrob Chemother
October 2020
Background: We conducted a prospective study in ICU patients of two tertiary hospitals in order to determine basic pharmacokinetic (PK) parameters, associated variation and target attainment rates for anidulafungin, micafungin and caspofungin.
Methods: Serum samples from patients treated for 7 days with the standard doses of anidulafungin (N = 13), micafungin (N = 14) or caspofungin (N = 7) were analysed by validated chromatographic methods. PK parameters determined with non-compartmental analysis were correlated with demographic, laboratory and disease severity characteristics.
Aims: The population pharmacokinetics (PK) of anidulafungin in critically ill patients hospitalized in intensive care units (ICUs) was explored with the intention of evaluating and optimizing dosing regimens.
Methods: A PK study was conducted in a cohort of 13 patients treated with anidulafungin using intensive sampling during multiple periods per patient and the high-performance liquid chromatography method for drug quantification. A population PK model was developed to describe the concentration-time course of anidulafungin and the inter-individual (IIV) and interoccasion variability (IOV) of the PK parameters.